Company Logo

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression treatment for depression and anxiety

For many people gripped by depression, traditional therapy and medications are not effective. Personalized treatment may be the solution.

Cue is an intervention platform that converts passively acquired sensor data from smartphones into personalised micro-interventions to improve mental health. We examined the most effective-fitting personalized ML models to each person, using Shapley values to determine their feature predictors. The results revealed distinct characteristics that deterministically changed mood over time.

Predictors of Mood

Depression is one of the leading causes of mental illness.1 However, only half of people suffering from the condition receive treatment1. To improve the outcomes, doctors must be able to identify and treat patients most likely to respond to certain treatments.

A customized depression treatment plan can aid. By using sensors on mobile phones, an artificial intelligence voice assistant and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new natural ways to treat Depression to predict which patients will benefit from the treatments they receive. Two grants were awarded that total over $10 million, they will use these tools to identify biological and behavioral predictors of responses to antidepressant medications as well as psychotherapy.

So far, the majority of research on factors that predict depression treatment effectiveness has centered on sociodemographic and clinical characteristics. These include demographics like gender, age and education as well as clinical characteristics like severity of symptom and comorbidities, as well as biological markers.

While many of these factors can be predicted from information in medical treatment for depression records, very few studies have utilized longitudinal data to study the causes of mood among individuals. Few studies also take into consideration the fact that mood can differ significantly between individuals. Therefore, it is essential to develop methods that allow for the identification of different mood predictors for each person and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to detect patterns of behavior and emotions that are unique to each individual.

In addition to these methods, the team created a machine learning algorithm to model the changing predictors of each person's depressed mood. The algorithm blends these individual characteristics into a distinctive "digital phenotype" for each participant.

This digital phenotype has been linked to CAT DI scores that are a psychometrically validated symptoms severity scale. The correlation was not strong however (Pearson r = 0,08, P-value adjusted for BH = 3.55 10 03) and varied significantly between individuals.

Predictors of symptoms

Depression is among the world's leading causes of disability1, but it is often untreated and not diagnosed. In addition an absence of effective treatments and stigmatization associated with depressive disorders prevent many people from seeking help.

To help with personalized treatment, it is essential to identify predictors of symptoms. However, the current methods for predicting symptoms are based on the clinical interview, which is unreliable and only detects a tiny number of symptoms that are associated with depression.2

Machine learning can improve the accuracy of diagnosis and treatment for depression treatment london by combining continuous digital behavioral phenotypes gathered from smartphones with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes capture a large number of unique behaviors and activities, which are difficult to capture through interviews, and allow for continuous, high-resolution measurements.

The study enrolled University of California Los Angeles (UCLA) students with mild to severe depressive symptoms enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29, which was developed under the UCLA Depression Grand Challenge. Participants were referred to online support or clinical care depending on the severity of their depression. Participants with a CAT-DI score of 35 65 were assigned to online support with the help of a peer coach. those with a score of 75 were routed to clinics in-person for psychotherapy.

Participants were asked a series of questions at the beginning of the study concerning their demographics and psychosocial traits. These included age, sex education, work, and financial status; if they were partnered, divorced, or single; current suicidal thoughts, intentions or attempts; and the frequency at the frequency they consumed alcohol. The CAT-DI was used to rate the severity of depression-related symptoms on a scale of zero to 100. The CAT-DI test was carried out every two weeks for those who received online support, and weekly for those who received in-person assistance.

Predictors of Treatment Response

Personalized depression treatment is currently a major research area, and many studies aim at identifying predictors that help clinicians determine the most effective drugs for each patient. Pharmacogenetics, in particular, uncovers genetic variations that affect the way that our bodies process drugs. This allows doctors to select the medications that are most likely to be most effective for each patient, reducing the time and effort involved in trials and errors, while eliminating any side effects that could otherwise hinder advancement.

Another approach that is promising is to build models of prediction using a variety of data sources, such as data from clinical studies and neural imaging data. These models can be used to determine which variables are most predictive of a particular outcome, like whether a drug will help with symptoms or mood. These models can be used to determine a patient's response to treatment that is already in place, allowing doctors to maximize the effectiveness of their current therapy.

A new generation of studies uses machine learning methods, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables to improve predictive accuracy. These models have proven to be useful in forecasting treatment outcomes, such as the response to antidepressants. These approaches are becoming more popular in psychiatry, and are likely to become the standard of future clinical practice.

In addition to ML-based prediction models The study of the underlying mechanisms of depression is continuing. Recent research suggests that depression is connected to dysfunctions in specific neural networks. This theory suggests that a individualized treatment for depression will depend on targeted therapies that restore normal functioning to these circuits.

One method to achieve this is by using internet-based programs which can offer an personalized and customized experience for patients. One study found that a web-based program was more effective than standard treatment in reducing symptoms and ensuring the best quality of life for patients suffering from MDD. In addition, a controlled randomized trial of a personalized approach to depression treatment showed steady improvement and decreased adverse effects in a large percentage of participants.

Predictors of Side Effects

A major obstacle in individualized depression treatment involves identifying and predicting the antidepressant medications that will have minimal or no side effects. Many patients are prescribed a variety of medications before finding a medication that is effective and tolerated. Pharmacogenetics is an exciting new avenue for a more effective and precise approach to choosing antidepressant medications.

A variety of predictors are available to determine the best antidepressant to prescribe, including gene variations, phenotypes of patients (e.g. gender, sex or ethnicity) and co-morbidities. To identify the most reliable and accurate predictors for a particular treatment, random controlled trials with larger numbers of participants will be required. This is due to the fact that the identification of moderators or interaction effects may be much more difficult in trials that take into account a single episode of treatment per participant instead of multiple sessions of treatment over time.

Furthermore, the estimation of a patient's response to a particular medication will also likely require information about comorbidities and symptom profiles, and the patient's prior subjective experience of its tolerability and effectiveness. Presently, only a handful of easily assessable sociodemographic and clinical variables appear to be reliable in predicting response to MDD, such as age, gender race/ethnicity, SES, BMI, the presence of alexithymia and the severity of depression symptoms.

Many challenges remain in the application of pharmacogenetics in the treatment of depression. It is crucial to have a clear understanding and definition of the genetic factors that cause depression, as well as a clear definition of an accurate indicator of the response to treatment. In addition, ethical issues such as privacy and the responsible use of personal genetic information must be carefully considered. In the long-term pharmacogenetics can be a way to lessen the stigma associated with mental health treatment and improve the outcomes of those suffering with depression. However, as with all approaches to psychiatry, careful consideration and implementation is required. For now, it is best to offer patients various depression medications that work and encourage them to talk openly with their doctor.